ESC 365 - Addressing cardiovascular risk in type 2 diabetes - The LEADER trial

ESC Premium Access

Addressing cardiovascular risk in type 2 diabetes - The LEADER trial

Event: ESC CONGRESS 2016

Topic: Diabetes management

Session type: Satellite Symposium

Sponsored by Novo Nordisk

Date: 28 August 2016

Time: 18:30 - 20:00

Session

5 presentations in this session

Introduction - Cardiovascular risk in diabetes and cardiovascular outcomes trials - Where do we come from?

Speaker: Professor L. Ryden (Stockholm, SE)

LEADER – Cardiovascular outcomes & the cardiologist’s perspective.

Speaker: Professor S. Nissen (Cleveland, US)

LEADER from the diabetologist’s perspective.

Speaker: Professor J. Petrie (Glasgow, GB)

Cardiovascular outcomes trials in diabetes – What have we learned?

Speaker: Doctor M. Husain (Toronto, CA)

Question and answers - Addressing cardiovascular risk in type 2 diabetes - The LEADER trial.

Speaker: Professor L. Ryden (Stockholm, SE)

5 speakers from this session

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)

31 presentations

0 follower

Professor Steven E Nissen

Cleveland Clinic Foundation, Cleveland (United States of America)

11 presentations

0 follower

Professor John R Petrie

, Glasgow (United Kingdom of Great Britain & Northern Ireland)

2 presentations

0 follower

Doctor Mansoor Husain

University of Toronto, Toronto (Canada)

7 presentations

1 follower

Professor Lars Ryden

Department of medicine, Karolinska Institutet, Stockholm, Stockholm (Sweden)

31 presentations

0 follower

This platform is supported by